With a market capitalization (market cap) of $4.83B — a measure of how much the company is worth — Cogent Biosciences, Inc. ranks #1,323 among the 2,402 companies tracked, and 163rd in Healthcare as of November 20, 2026. Shares trade at $27.74, down 0.25% on the day.
As of November 20, 2026 · Prices may be delayed
of 2,402 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 13, 2026. The headline market cap is from the ranking update on November 20, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 13, 2026 | $4.94B | -13.53% | $28.56 |
| 2025 | Dec 31, 2025 | $5.72B | +563.65% | $35.52 |
| 2024 | Dec 31, 2024 | $861.6M | +68.95% | $7.80 |
| 2023 | Dec 29, 2023 | $509.97M | -37.42% | $5.88 |
Ranking figure $4.83B as of November 20, 2026.
Market cap = share price × shares outstanding.
Cogent Biosciences, Inc.'s ranking market cap is the reported market cap from the latest ranking update, with a share price of $27.74 as of November 19, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $4.94B on November 13, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 160,980,024 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $4.47B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $27.74.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #12 | Eli Lilly and Company LLY | $1.27T | -2.29% |
| #21 | Johnson & Johnson JNJ | $643.09B | -2.04% |
| #24 |
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST).
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 20, 2026, Cogent Biosciences, Inc. (COGT) is worth $4.83B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Cogent Biosciences, Inc.’s book equity is about $636.37M. Market cap is the market value of the outstanding shares. As of November 20, 2026, its market cap is $4.83B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Cogent Biosciences, Inc. ranks #1,323 among the 2,402 companies tracked on MarketCapLens. In Healthcare it ranks #163 of 350.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 | Dec 30, 2022 | $814.86M | +116.80% | $11.56 |
|---|
| 2021 | Dec 31, 2021 | $375.85M | — | $8.58 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Undefined when revenue is zero
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $501.19B |
| -0.86% |
| #35 | Merck & Co., Inc. MRK | $327.24B | -3.66% |
| #38 | UnitedHealth Group Incorporated UNH | $296.12B | -5.55% |
| #41 | Novartis AG NVS | $285.6B | -2.57% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1320 | Eastern Bankshares, Inc. EBC | $4.84B | -2.80% |
| #1321 | HA Sustainable Infrastructure Capital, Inc. HASI | $4.84B | -2.03% |
| #1322 | Floor & Decor Holdings, Inc. FND | $4.83B | -3.48% |
| #1324 | Silicon Motion Technology Corporation SIMO | $4.82B | -3.72% |
| #1325 | DPC Holdings Ltd. DPC | $4.82B | +7.08% |
| #1326 | Klarna Group plc KLAR | $4.8B | -12.32% |
Cogent Biosciences, Inc.’s ranking market cap of $4.83B comes from the same snapshot as the rest of this site, as of November 20, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 160,980,024. The historical market-cap series last observed $4.94B on November 13, 2026.
Over the past year, Cogent Biosciences, Inc.’s market cap is down 9.21%, using historical market-cap records rather than today’s share count applied to past prices.
Cogent Biosciences, Inc. (COGT) shares trade at $27.74, down 0.25% on the day, as of November 20, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.